DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+18.6%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$6.69B
AUM Growth
+$6.69B
(+11%)
Cap. Flow
-$45.5M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
54.02%
Holding
681
New
246
Increased
84
Reduced
73
Closed
235
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$72.1M |
| 2 |
Indivior
INDV
|
$49.7M |
| 3 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$45.7M |
| 4 |
Merus
MRUS
|
$32.9M |
| 5 |
Viatris
VTRS
|
$30.2M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$102M |
| 2 |
Surgery Partners
SGRY
|
$94.4M |
| 3 |
Catalyst Pharmaceutical
CPRX
|
$57.6M |
| 4 |
BioNTech
BNTX
|
$49.8M |
| 5 |
Integra LifeSciences
IART
|
$42.8M |
Sector Composition
| 1 | Healthcare | 87.45% |
| 2 | Industrials | 0.72% |
| 3 | Technology | 0.55% |
| 4 | Financials | 0.42% |
| 5 | Consumer Discretionary | 0.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Edgewise Therapeutics
EWTX
$1.54B
| $47.5M | 0.71% |
1,781,006
-1,093,580
| -38% | -$29.2M |
|
|
BCAX
27
Bicara Therapeutics Inc. Common Stock
BCAX
$655M
| $45.7M | 0.68% |
+1,795,174
| New | +$45.7M |
|
28
CONMED
CNMD
$1.64B
| $44.2M | 0.66% |
614,890
-16,374
| -3% | -$1.18M |
|
29
Galapagos
GLPG
$2.06B
| $40.6M | 0.61% |
1,411,000
| – | – |
|
30
Cogent Biosciences
COGT
$1.83B
| $40.4M | 0.6% |
3,744,263
| – | – |
|
31
Alnylam Pharmaceuticals
ALNY
$58.6B
| $39.9M | 0.6% |
145,000
+25,200
| +21% | +$6.93M |
|
32
Enhabit
EHAB
$398M
| $39.5M | 0.59% |
4,997,746
| – | – |
|
33
Embecta
EMBC
$837M
| $38.5M | 0.58% |
2,730,343
+4,208
| +0.2% | +$59.3K |
|
34
Pharvaris
PHVS
$1.41B
| $37.6M | 0.56% |
2,031,700
+634,421
| +45% | +$11.7M |
|
35
Perspective Therapeutics
CATX
$251M
| $37.6M | 0.56% |
2,817,763
| – | – |
|
36
Structure Therapeutics
GPCR
$1.14B
| $37.1M | 0.55% |
844,407
| – | – |
|
37
Day One Biopharmaceuticals
DAWN
$766M
| $36.5M | 0.54% |
2,617,713
-305,424
| -10% | -$4.25M |
|
38
10x Genomics
TXG
$1.66B
| $34.1M | 0.51% |
1,508,943
+911,943
| +153% | +$20.6M |
|
39
CG Oncology
CGON
$2.19B
| $32.1M | 0.48% |
850,695
+417,155
| +96% | +$15.7M |
|
40
DocGo
DCGO
$152M
| $30.1M | 0.45% |
9,066,138
+1,870,182
| +26% | +$6.21M |
|
41
Foghorn Therapeutics
FHTX
$298M
| $28.2M | 0.42% |
3,027,886
+509,386
| +20% | +$4.74M |
|
|
MREO
42
Mereo BioPharma
MREO
$275M
| $27.6M | 0.41% |
6,710,429
| – | – |
|
43
Savara
SVRA
$591M
| $27.4M | 0.41% |
+6,465,777
| New | +$27.4M |
|
44
InMode
INMD
$917M
| $26.8M | 0.4% |
1,578,708
+412,004
| +35% | +$6.98M |
|
45
PACS Group
PACS
$1.71B
| $26.5M | 0.4% |
663,851
| – | – |
|
|
ZBIO
46
Zenas BioPharma, Inc. Common Stock
ZBIO
$722M
| $26.4M | 0.4% |
+1,562,942
| New | +$26.4M |
|
47
Lantheus
LNTH
$3.75B
| $26.4M | 0.39% |
240,218
| – | – |
|
48
Vaxcyte
PCVX
$4.17B
| $25.7M | 0.38% |
+225,000
| New | +$25.7M |
|
49
Insulet
PODD
$24.2B
| $25.5M | 0.38% |
109,600
-2,833
| -3% | -$659K |
|
|
50
BioNTech
BNTX
$24.1B
| $20.7M | 0.31% |
174,500
-419,500
| -71% | -$49.8M |
|